Product Description
Mechanisms of Action: Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Germany | Ireland | Italy | Korea | Malta | Saudi Arabia | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2000034023 | N/A |
Not yet recruiting |
Urinary Tract Infections |
2022-06-30 |
|
| ChiCTR2000040064 | N/A |
Not yet recruiting |
Neonatal Sepsis |
2021-12-31 |